Fig. 2From: Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targetsThe timeline of FDA-approved drugs for hepatocellular carcinoma (HCC). Abbreviations: OS, overall survival; ORR, objective response rate; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; FGFR, fibroblast growth factor receptor; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand 1; CTLA-4, cytotoxic T lymphocyte-associated antigen-4Back to article page